2023 White Paper on Recent Issues in Bioanalysis : ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard
The 17th Workshop on Recent Issues in Bioanalysis (17th WRIB) took place in Orlando, FL, USA on June 19-23, 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 17th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week to allow an exhaustive and thorough coverage of all major issues in bioanalysis of biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on "EU IVDR 2017/746 Implementation and impact for the Global Biomarker Community: How to Comply with these NEW Regulations" and on "US FDA/OSIS Remote Regulatory Assessments (RRAs)" were the special features of the 17th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2023 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2023 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations on Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity. Part 1A (Mass Spectrometry Assays and Regulated Bioanalysis/BMV), P1B (Regulatory Inputs) and Part 2 (Biomarkers, IVD/CDx, LBA and Cell-Based Assays) are published in volume 16 of Bioanalysis, issues 8 and 9 (2024), respectively.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Bioanalysis - 16(2024), 7 vom: 23. März, Seite 77-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mora, Johanna [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Bioanalysis |
|---|
| Anmerkungen: |
Date Completed 26.03.2024 Date Revised 26.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/bio-2024-0024 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368793893 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368793893 | ||
| 003 | DE-627 | ||
| 005 | 20240326235517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2024-0024 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1348.xml |
| 035 | |a (DE-627)NLM368793893 | ||
| 035 | |a (NLM)38389403 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mora, Johanna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 2023 White Paper on Recent Issues in Bioanalysis |b ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.03.2024 | ||
| 500 | |a Date Revised 26.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The 17th Workshop on Recent Issues in Bioanalysis (17th WRIB) took place in Orlando, FL, USA on June 19-23, 2023. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest in bioanalysis. The 17th WRIB included 3 Main Workshops and 7 Specialized Workshops that together spanned 1 week to allow an exhaustive and thorough coverage of all major issues in bioanalysis of biomarkers, immunogenicity, gene therapy, cell therapy and vaccines. Moreover, in-depth workshops on "EU IVDR 2017/746 Implementation and impact for the Global Biomarker Community: How to Comply with these NEW Regulations" and on "US FDA/OSIS Remote Regulatory Assessments (RRAs)" were the special features of the 17th edition. As in previous years, WRIB continued to gather a wide diversity of international, industry opinion leaders and regulatory authority experts working on both small and large molecules as well as gene, cell therapies and vaccines to facilitate sharing and discussions focused on improving quality, increasing regulatory compliance, and achieving scientific excellence on bioanalytical issues. This 2023 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2023 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 3) covers the recommendations on Gene Therapy, Cell therapy, Vaccines and Biotherapeutics Immunogenicity. Part 1A (Mass Spectrometry Assays and Regulated Bioanalysis/BMV), P1B (Regulatory Inputs) and Part 2 (Biomarkers, IVD/CDx, LBA and Cell-Based Assays) are published in volume 16 of Bioanalysis, issues 8 and 9 (2024), respectively | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a WRIB | |
| 650 | 4 | |a bioanalysis | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a cell therapy | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Palmer, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Leslie |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Bonnie |e verfasserin |4 aut | |
| 700 | 1 | |a Partridge, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Meena |e verfasserin |4 aut | |
| 700 | 1 | |a Sonderegger, Ivo |e verfasserin |4 aut | |
| 700 | 1 | |a Smeraglia, John |e verfasserin |4 aut | |
| 700 | 1 | |a Bivi, Nicoletta |e verfasserin |4 aut | |
| 700 | 1 | |a Dakappagari, Naveen |e verfasserin |4 aut | |
| 700 | 1 | |a Diebold, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Garofolo, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Grimaldi, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Kalina, Warren |e verfasserin |4 aut | |
| 700 | 1 | |a Kamerud, John |e verfasserin |4 aut | |
| 700 | 1 | |a Kar, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, Jean-Claude |e verfasserin |4 aut | |
| 700 | 1 | |a Mayer, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Melton, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Merdek, Keith |e verfasserin |4 aut | |
| 700 | 1 | |a Nolan, Katrina |e verfasserin |4 aut | |
| 700 | 1 | |a Picard, Serge |e verfasserin |4 aut | |
| 700 | 1 | |a Shao, Weiping |e verfasserin |4 aut | |
| 700 | 1 | |a Seitzer, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yoichi |e verfasserin |4 aut | |
| 700 | 1 | |a Tounekti, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Vigil, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Walravens, Karl |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Weifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yuanxin |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Verthelyi, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Kubiak, Robert J |e verfasserin |4 aut | |
| 700 | 1 | |a Coble, Kelly |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Swati |e verfasserin |4 aut | |
| 700 | 1 | |a Abhari, Mohsen Rajabi |e verfasserin |4 aut | |
| 700 | 1 | |a Richards, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ullmann, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Calderon, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Cludts, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Gunn, George R |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Ishii-Watabe, Akiko |e verfasserin |4 aut | |
| 700 | 1 | |a Manangeeswaran, Mohanraj |e verfasserin |4 aut | |
| 700 | 1 | |a Maxfield, Kimberly |e verfasserin |4 aut | |
| 700 | 1 | |a McCush, Fred |e verfasserin |4 aut | |
| 700 | 1 | |a O'Day, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Poetzl, Johann |e verfasserin |4 aut | |
| 700 | 1 | |a Rasamoelisolo, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Saad, Ola M |e verfasserin |4 aut | |
| 700 | 1 | |a Scheibner, Kara |e verfasserin |4 aut | |
| 700 | 1 | |a Shubow, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Thacker, Seth |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d 2009 |g 16(2024), 7 vom: 23. März, Seite 77-119 |w (DE-627)NLM196969840 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:7 |g day:23 |g month:03 |g pages:77-119 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/bio-2024-0024 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 7 |b 23 |c 03 |h 77-119 | ||